Top 10 Companies in the Global Zonisamide Market: Global Share, Market Size, Revenue Report (2024–2035)
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
Growing awareness of early diagnosis, an increase in the use of adjuvant medicines to improve seizure control, and an increase in the prevalence of epilepsy and other neurological illnesses are driving the zonisamide market. Zonisamide suppresses seizures via a variety of ways. Demographics of all ages are being caught to the epilepsy, a chronic, non-communicable brain disorder. With the right diagnosis and care, the majority of people with epilepsy are thought to be able to live seizure-free lives. Moreover, the rising incidence of epilepsy has led to an increase in the prevalence of stroke, dementia, and brain tumours in the elderly population. One class of medications that is anticipated to have a significant market share over the projection period is second-generation antiepileptic medications. Zonisamide is a medication of the second generation. Demand is also supported by growing off-label usage and formulation improvements for improved patient compliance.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of The Global Zonisamide Market
Zonisamide Market Size & Statistics
- The Market Size for Zonisamide Was Estimated to be worth USD 380.1 Million in 2024.
- The Market Size is Going to Expand at a CAGR of 4.9% between 2025 and 2035.
- The Global Zonisamide Market Size is anticipated to reach USD 644.57 Million by 2035.
- North America is estimated to dominate the market during the forecast period in the Zonisamide Market.
- Asia-Pacific is projected to grow the fastest during the forecast period in the Zonisamide Market.
Regional growth and demand
North America is expected to dominate the market during the forecast period in the zonisamide market.
North America held the majority of the market share by revenue for the zonisamide market. With a majority of market share in 2024, the North America segment dominates the zonisamide industry. This is a result of the growing epileptic population in the North American continent. In 2021, the North American market for antiepileptic medications was estimated to be worth US$7.97 billion. With a positive government initiative to strengthen the healthcare system, a well-developed healthcare infrastructure, and increasingly substantial R&D activity in the region, North America dominates the market for epilepsy treatments.
Asia-Pacific is projected to grow the fastest during the forecast period in the zonisamide market.
Asia-Pacific is projected to grow the fastest during the forecast period in the zonisamide market. The Asia Pacific area is expected to see the quickest growth rate across the planned period. Rising healthcare costs, growing knowledge of epilepsy, and a growing number of pharmaceutical corporations aiming for these areas are among the forces driving this growth. Particularly awaited is the amazing market growth in emerging economies such as China and India.
Top 10 Trends in the Zonisamide Market
- Steady Market Growth and High Compound Annual Growth Rate
- Extension into the Management of Parkinson's Disease
- High Generic Competition Prevalence
- Transition to Once-Daily Dose
- Growing Off-Label Use in Neurology
- Focus on Pediatric Epilepsy Treatment
- Increase Adoption in Asia-Pacific and North America
- Refractory Epilepsy Management
- Regulatory Focus on Safety Profiles
- Impact of API Cost Fluctuations
1.Steady Market Growth and High Compound Annual Growth Rate
Due to growing epilepsy cases and growing therapeutic solutions utilization, the market is expected to increase at a CAGR of 3.8% between 2025 and 2033 globally.
2.Extension into the Management of Parkinson's Disease
Zonisamide is being used more frequently to treat motor irregularities in severe Parkinson's disease in addition to epilepsy, and there is clinical data to support its effectiveness.
3.High Generic Competition Prevalence
With high market dominance by generic producers like Teva, Sun Pharma, and Zydus, there is fierce price competition and broad availability in the market.
4.Transition to Once-Daily Dose
People are increasingly shifting towards one dose a day administration and moving away from multiple daily doses, in order to increase patient compliance and adherence.
5.Growing Off-Label Use in Neurology
Bipolar disorder, binge-eating disorder, essential tremors, and neuropathic pain are among the types of disorders for which zonisamide is being used for reliable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of The Global Zonisamide Market
Top 10 Companies Leading the Zonisamide Market
- Eisai Co.
- Sumitomo Pharma
- Sun Pharma
- Teva Pharma
- Viatris
- Glenmark Pharma
- Zydus Life
- Amneal Pharma
- Apotex Inc.
- Advanz Pharma
1.Eisai Co.
Headquarters: Tokyo, Japan
The Eisai Co. is a Japanese pharmaceutical company. In 2024, its overall revenue was about $5.05 billion. Moreover, its establishment was in 1941, whereas its main product line consists of Zonegran, Leqembi, Lenvima, OTC drugs, and Generic. Additionally, it has excellent focus and investment in R&D. China, India, the United States, and the United Kingdom are its primary operating nations. Additionally, it has retained the worldwide brand rights for zonisamide.
2.Sumitomo Pharma
Headquarters: Osaka, Japan
It is an establishment of 1897 with revenue for the year 2024 estimated to be approximately of $ 2.6 billion. Its core product range consists of Excegran, Orgovyx, and Gemtesa. The majority of working sites are in Japan, the USA, and China. Moreover, it was the first company to discover zonisamide, and it markets it as Excegran.
3.Sun Pharma
Headquarters: Mumbai, India
Dilip Shanghvi, in 1983, formed Sun Pharma. It is India’s largest company by market share in the pharmaceutical sector, with its business operations working globally with 43 sites. It specialises in Generics, Speciality CNS. Its 2024 gross revenue was around $6.3 billion.
4.Teva Pharma
Headquarters: Tel Aviv, Israel
It is an establishment of 1901 and had revenue of $17.3 billion in 2024 through its global operations. Moreover. It is the largest company by market share in the pharmaceutical sector by volume in the world, and mainly in Generics, Austedo, and Ajovy.
5.Viatris
Headquarters: Pennsylvania, USA
The company was started in 1961, and its recent revenue was of $15.4 billion for 2024 and has a core product portfolio consisting of generic brands. Moreover, it has business operations in 50+ locations around the world. It basically came into the market through the merger of Mylan-Upjohn and also a major EU supplier.
Are you ready to discover more about the Zonisamide Market?
The report provides an in-depth analysis of the leading companies operating in the global zonisamide market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardised format that includes:
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of The Global Zonisamide Market
Company Profile
- Eisai Co.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
Our Report
https://www.sphericalinsights.com/reports/japan-fresh-fruits-market
https://www.sphericalinsights.com/reports/italy-contraceptive-devices-market
https://www.sphericalinsights.com/reports/italy-cybersecurity-market
https://www.sphericalinsights.com/reports/italy-beauty-and-personal-care-market
Conclusion
The global zonisamide market size is expected to grow at a compound annual growth rate (CAGR) of 4.9%, from USD 380.1 million in 2024 to USD 644.57 million by 2035. Global market expansion is fuelled by growing awareness of early diagnosis, an increase in the use of adjuvant medicines to improve seizure control, and an increase in the prevalence of epilepsy and other neurological illnesses. The North America segment dominates the zonisamide industry. This is a result of the growing epileptic population in the North American continent. The Asia Pacific area is expected to see the quickest growth rate across the planned period. Rising healthcare costs, growing knowledge of epilepsy, and a growing number of pharmaceutical corporations aiming for these areas are among the forces driving this growth.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?